MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Molecular Insight Pharmaceuticals, Inc
Finance & Acquisitions: Molecular Insights
IPO (2007)
Medivation (NASDAQ: MDVN)
Organization & Developments: Medivation
Parents
Medivation (NASDAQ: MDVN)
Children
2016: Medivation Rejects Sanofi’s Buyout Bid; Sanofi ‘Remains Committed’
2016: Medivation Up On Cancer Data, New Buyout Buzz
2016: Medivation’s sole commercial product is prostate-cancer drug Xtandi, marketed by Japan’s Astellas.
An experimental drug for Huntington’s disease failed in a pivotal clinical trial. (2011)
Biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quick
Current product pipeline consists of small-molecule drugs in development to treat three large, unmet medical needs:
Have created a portfolio of therapies with the potential to revolutionize medical practice.
Hormone-refractory prostate cancer
Jumps
*Key People: Medivation
Finance & Acquisition: Medivation